Brief: Atea Pharmaceuticals Announces Continued Advancement Of Global Phase 3 Hcv Program
24/06/2025 12:08
June 24 (Reuters) - Atea Pharmaceuticals Inc AVIR.O: ATEA PHARMACEUTICALS ANNOUNCES CONTINUED ADVANCEMENT OF GLOBAL PHASE 3 HCV PROGRAM WITH DOSING OF FIRST PATIENT IN C-FORWARD OUTSIDE NORTH AMERICA Source text: ID:nGNX6YSVpf Further company coverage: AVIR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atea Pharmaceuticals
See all newsAtea Pharmaceuticals Q2 loss narrows as HCV trial expenses decline
Atea Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
Atea Pharmaceuticals, Inc. expected to post a loss of 56 cents a share - Earnings Preview
NASDAQ RESUMED AT 07:30 AM